Proteomics

Dataset Information

0

CDK4/6 inhibitor resistance in prostate cancer

ABSTRACT: CDK4/6 kinase inhibitors have shown great promise in clinical trials in various cancer types and have recently entered clinical trial for advanced prostate cancer. Although patients are expected to respond well to this class of drugs, development of resistance in some patients is anticipated. To pre-empt this and study how prostate cancer may evade CDK4/6 inhibition, new resistance models were generated from LNCaP and LAPC4 prostate cancer cells cells by prolonged culturing in presence of 0.5uM palbociclib. A shotgun phosphoproteomics approach was utilized and integrated with RNA sequencing data to unravel the molecular underpinnings of acquired resistance to palbociclib and resultant broad CDK4/6 inhibitor resistance.

OTHER RELATED OMICS DATASETS IN: PRJNA389297

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell, Cell Culture

DISEASE(S): Prostate Cancer

SUBMITTER: Zhen Li  

LAB HEAD: Justin M. Drake

PROVIDER: PXD006561 | Pride | 2018-05-16

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
QE02727-2.raw Raw
QE02727.raw Raw
QE02728-2.raw Raw
QE02728.raw Raw
QE02729-2.raw Raw
Items per page:
1 - 5 of 42
altmetric image

Publications

<b>Purpose:</b> Loss of cell-cycle control is a hallmark of cancer, which can be targeted with agents, including cyclin-dependent kinase-4/6 (CDK4/6) kinase inhibitors that impinge upon the G<sub>1</sub>-S cell-cycle checkpoint via maintaining activity of the retinoblastoma tumor suppressor (RB). This class of drugs is under clinical investigation for various solid tumor types and has recently been FDA-approved for treatment of breast cancer. However, development of therapeutic resistance is not  ...[more]

Similar Datasets

Proteomics RET Kinase Inhibition in Neuroendocrine Prostate Cancer, part 2
2020-05-29 | PXD012971 | Pride
Proteomics RET Kinase Inhibition in Neuroendocrine Prostate Cancer, part 1
2020-05-29 | PXD012970 | Pride
Transcriptomics CDK4/6 inhibitor resistance in prostate cancer
2018-05-31 | GSE99675 | GEO
Transcriptomics RNA sequencing of luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitors
2024-11-18 | E-MTAB-14085 | biostudies-arrayexpress
Proteomics O-GlcNAcylation promotes Palbociclib resistance in breast cancer by regulating MITF nuclear translocation
2024-05-30 | PXD042763 | Pride
Transcriptomics Genome wide transcriptome analysis of palbociclib or GSK3326595 treated A375 cells [Palbociclib_GSK_RNASeq]
2019-08-23 | GSE133568 | GEO
Transcriptomics Gene expression alterations associated with acquired-resistance to the CDK4/6 inhibitor palbociclib [Palbociclib resistance_RNASeq]
2019-08-23 | GSE133567 | GEO
Proteomics O-GlcNAcylation promotes Palbociclib resistance in breast cancer by regulating MITF nuclear translocation
2024-05-30 | PXD042838 | Pride
Transcriptomics Activation of the interferon signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer [RNA-seq]
2021-12-04 | GSE150997 | GEO
Genomics O-GlcNAcylation promotes Palbociclib resistance in breast cancer by regulating MITF nuclear translocation [ChIP-seq]
2023-10-10 | GSE234515 | GEO